Table 2.
Predictors of use of BZDs and Z-drugs among HIV-infected patients and the controls.
| Characteristics | Any use of BZDs and Z-drugs* | Long-term use of BZDs and Z-drugs∗,# | ||
|---|---|---|---|---|
| OR (95% CI) | P value | OR (95% CI) | P value | |
| HIV, presence versus absence | 8.70 (6.82~10.97) | <0.001 | 5.06 (3.63~7.04) | <0.001 |
| Psychiatric comorbidities, presence versus absence | ||||
| Any mood disorder | 9.86 (5.37~18.12) | <0.001 | 15.69 (10.18~24.17) | <0.001 |
| Any anxiety disorder | 7.24 (3.57~14.67) | <0.001 | 6.53 (4.34~9.82) | <0.001 |
| Alcohol use disorder | 3.21 (0.72~14.43) | 0.128 | 1.55 (0.29~8.38) | 0.621 |
| Substance use disorder | 1.26 (0.83~1.92) | 0.281 | 2.33 (1.49~3.64) | <0.001 |
| Insomnia | 20.09 (10.49~38.47) | <0.001 | 10.69 (7.46~15.31) | <0.001 |
*Adjusted for demographic data and psychiatric comorbidities and HIV as a binary variable.
#Long-term use of BZDs and Z-drugs means cumulative defined daily dose ≧180.
OR: odds ratio; CI: confidence interval.
Bold type indicates the statistical significance.